INTRODUCTION
Patients with human immunodeficiency virus (HIV) infection are at risk for several infections that can be prevented by immunizations. The potential benefits of immunization are clear. However, HIV disease may influence the risk for adverse events and the effectiveness of the vaccines.
HIV destroys CD4+ T cells and creates an environment of inappropriate immune activation rendering even the uninfected T cells and B cells dysfunctional.
Therefore, both responses to T cell-dependent antigens (e.g. protein-derived vaccines) and T cell-independent antigens (e.g. polysaccharide vaccines) are affected.
The immune response decreases as the HIV disease progresses. Fortunately, in this era of highly active antiretroviral therapy (HAART), new evidence suggests that one's ability to mount an immune response to vaccines can be restored to that of HIVuninfected persons [52, 65] Types of vaccines do influence the nature of immune response. Vaccines using T-dependent antigens stimulate production of long-lasting cell-mediated and humoral immune responses, while T-independent antigenetic vaccines do not induce T-cell memory, and booster doses are not expected to produce substantially increased protection [15] . The response to higher doses of vaccine and the persistence of antibody in HIV-infected persons have not been systematically evaluated. Although higher doses or more frequent boosters may be considered for these patients, firm recommendation cannot be made [13] . Live viral vaccines evoke a stronger and a more rapid immune response even after a single dose. In contrast, inactivated vaccines usually require more doses and longer time before adequate immunity is produced. However, in immunocompromised hosts, live viral vaccines have to be used with caution. Unlike patients with primary T-cell immunodeficiency such as severe combined immune deficiency in which live viral vaccines are absolutely contraindicated, HIV-infected persons usually have some preserved immunity; therefore, many live viral vaccines can be given to patients with mild HIV disease.
Another important issue is whether vaccines can worsen HIV disease by inducing CD4+ T cell activation, resulting in more production of HIV virions.
Several studies have shown transient increase in plasma viremia after immunization [56, 63, 67, 73, 78] . However, this phenomenon is not always true according to other studies [25, 34] and likely does not bear clinical significance.
The objectives of this article are to summarize principles and suggest recommendations for vaccinating HIV-infected persons.
INACTIVATED VACCINES
In general, there is no harm in vaccinating HIV-infected patients with inactivated vaccines although antibody response may be impaired especially in symptomatic HIV-infected patients. It is universally recommended that HIV-infected patients be immunized as soon as age-appropriate with these inactivated vaccines [3] .
Hepatitis B virus (HBV) vaccine
Studies in infants born to HIV-infected mothers showed that children who 3 became infected with HIV responded poorly to HBV vaccine and the duration of protection was less, as compared to children who were not infected [7, 68, 76, 83, 85] .
One study showed that the antibody response depended on CD4+ T cell count [68] .
After completing vaccination with three conventional doses, the anti-HBs response of such persons should be measured, and those without protected antibody levels should be re-vaccinated with additional doses. Higher vaccine doses or increased number of doses may be required, however, firm recommendations cannot be made.
Watanaveeradej V et al studied antibody response to HBV vaccine in infants of HIV-positive mothers and found that the vaccine was well tolerated. The vaccine response rate of the HIV-infected group was 2/6 (33.3%), which was significantly lower than 20/21 (95.2%) for the HIV-uninfected group. Geometric mean antibody titers (GMTs) were 225.5 and 342.0 IU/L in the HIV-infected and HIV-uninfected groups, respectively [83] .
Diphtheria and tetanus toxoids, and pertussis (DTPw/DTPa,DT/dT/dTpa) vaccine.
For HIV-infected children, DTP vaccine is indicated at the same schedule and dosing as for immunocompetent children. Acellular pertussis vaccine in the combined DTPa vaccine is preferred and is commonly used in developed countries because it has fewer side effects whereas whole cell pertussis vaccine in the combined DTPw vaccine is less costly and used more in developing countries. dT or dTpa vaccines can be used as a booster dose in HIV-infected adults.
Immunity against tetanus in HIV-infected patients tended to be similar to that of age-matched normal population, whereas the immunity to diphtheria was usually lower and might require re-vaccination especially in HIV-infected patients living or 4 traveling to areas where diphtheria exposure is possible [41, 42, 48, 69] . Limited data is known about the antibody response to pertussis vaccine in HIV-infected persons.
Kroon FP et al found that after vaccination with diphtheria and tetanus toxoid, 61-73% and 78-100% of HIV-infected adults developed protective antibody titers of diphtheria and tetanus toxin, respectively. The mean titers of antibodies to diphtheria and tetanus were significantly lower in HIV-infected patients especially in those whose CD4+ T cell count was less than 200 cells/mm 3 [42] .
Inactivated poliovirus (IPV) vaccine
IPV vaccine is the preferred poliovirus vaccine for HIV-infected patients. This vaccine eliminates the risk of vaccine-associated polio paralysis (VAPP) seen with oral poliovirus vaccine (OPV). However, the antibody response of IPV vaccine in HIV-infected adults was poor and correlated with CD4+ T cell count [42, 79] .
Vardinon N et al found that the rise in anti-poliovirus antibody titer after IPV administration was noted in HIV-infected subjects whose CD4+ T cell count was greater than 200 cells/mm 3 whereas the group with low CD4+ T cell count failed to respond [79] . have HIV infection and were successfully treated with HAART had detectable antibody levels to Hib and 3 of the 4 (75%) without detectable antibodies seroconverted after re-immunization [52] .
Haemophilus influenzae

Pneumococcal vaccine
HIV-infected patients have a high risk of pneumococcal infections [19] . A study from Thailand showed that several children with invasive pneumococcal infection were HIV-infected and a number of cases were caused by drug-resistant pneumococci [58] .
There are two types of pneumococcal vaccines, the recently developed proteinderived or pneumococcal conjugate vaccine and the polysaccharide-derived vaccine.
In children, the pneumococcal conjugate vaccine is the preferred choice as it can elicit immune responses in children younger than 24 months while the polysaccharide vaccine cannot. Studies in HIV-infected children comparing the two types of vaccines have also demonstrated the conjugate vaccine to be significantly more immunogenic [13] . In HIV-infected Uganda adults, the occurrences of invasive pneumococcal diseases were not different in patients who received polysaccharide pneumococcal vaccine versus those who received placebo. Moreover, the patients who received the vaccine had higher prevalence of pneumonia from all causes [22] .
A study comparing antibody responses using pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in HIV-infected adults did not find a significant difference between the two vaccines [20] . Nevertheless, available data suggests superior antibody responses with conjugate vaccine; therefore, it should also be the 6 preferred choice in HIV-infected adults.
Studies have documented that the antibody production to pneumococci after vaccination with either conjugate or polysaccharide vaccines were lower in HIVinfected patients than in healthy control subjects, and the seroconversion rate was low in patients with low CD4+ T cell count [1, 11, [35] [36] [37] 44, 64, 84] . Slightly better responses were found with the conjugate vaccines [35] . Higher antibody concentrations were achieved after sequential vaccination with conjugate and polysaccharide vaccines [46] . In countries where pneumococcal conjugate vaccine is not available, unconjugate polysaccharide vaccine can be used as an alternative, usually after the age of two. Most evidence supports giving the vaccine as early as possible in the course of HIV infection in order to achieve the optimal antibody response.
Influenza vaccine
Influenza may cause severe complications in HIV-infected patients leading to increases in hospitalization and mortality. Annual influenza vaccine is recommended for HIV-infected children and adults. The antibody response to all types of influenza vaccines may be low in patients with advanced HIV-related illnesses and correlates with the number of CD4+ T cell count [8, 16, 30, 38, 39, 47] .
A review of published studies indicates that vaccination against influenza is well tolerated in both children and adults with HIV, but response to vaccination is lower than that observed in immunocompetent individuals. There have been studies
reporting that immunization against influenza may stimulate an increase of HIV viral load and decrease of CD4+ T cell count [56, 63, 67] . The increased viral replication is usually transient and it is difficult to determine a clear, measurable progression of the 7 underlying HIV disease [86] . Therefore, vaccination against influenza can be safely administered to HIV-infected patients. skin test) of HIV-infected children performed at the age of 9 months were less than those of HIV-uninfected children [74] . A few preliminary studies concerning other mycobacterial vaccines have been done [18, 80, 81] . These vaccines may have a role for the prevention of HIV-associated tuberculosis in the near future.
Oral poliovirus (OPV) vaccine
The benefits of poliovirus vaccines exceeds the potential risks in HIV-infected children. In most developed countries, OPV vaccine is no longer routinely recommended for use in HIV-infected children and members of their households.
However, although a few cases of VAPP have been developed after receiving OPV, many hundreds of thousands of HIV-infected children have been immunized, with no convincing evidence that the risk of developing VAPP is increased in HIV-infected children [17, 51, 58, 69] . Moreover, IPV vaccine is not always available in many developing countries and costs a lot more than OPV vaccine. OPV vaccine also has superior ability to induce intestinal immunity important for protection against wild poliovirus. Thus, many infectious disease experts from limited resource countries accept the use of OPV vaccine in HIV-infected children.
Measles vaccine or Measles-Mumps-Rubella (MMR) vaccine
Measles can be a life-threatening infection in immunocompromised hosts
including HIV-infected persons [33] . A frequent complication, pneumonitis, is associated with high mortality rates especially in the non-immunized.
The benefit of measles vaccine surpasses the potential risk in HIV-infected children. However, there has been a case report of an HIV-infected adult with severe immunologic suppression who developed progressive fatal pneumonitis after receiving measles vaccine [4, 14, 82] . 
Varicella-zoster virus (VZV) vaccine
HIV-infected children may be at an increased morbidity risk from varicella and herpes zoster. Limited data on varicella immunization of HIV-infected in CDC immunologic category 1 indicates that the vaccine is safe, immunogenic, and 11 effective. Pneumonia caused by varicella vaccine was reported in an HIV-infected patient [72] . Weighing potential and benefit risks, varicella vaccine should be considered for HIV-infected children in CDC categories N1 (no symptoms) and A1
(mild symptoms with CD4+ T cell > 24%). Symptomatic HIV-infected persons exposed to varicella should be considered susceptible regardless of their history of immunization and should receive varicella zoster immunoglobulin.
Levin MJ et al studied the safety and immunogenicity of VZV vaccine in children with mildly symptomatic HIV infection (N1 and A1) and found that the vaccine was safe and associated with only mild local and systemic reactions.
Vaccination also had no effect on the HIV disease progression or on the HIV viral load. However, the antibody response was impaired, with only 60% of subjects having anti-VZV antibody [49] .
OTHERS
Rabies vaccine
Dog bites are a serious public health problem in developing countries. In
Thailand, more than a quarter of victims were children [59] . With HAART therapy, HIV-infected children tend to live longer [61] , thus they may be at risk for rabies exposure.
The WHO Expert Committee on Rabies recommended using a double dose of rabies vaccine, given at different sites, for subjects who are immunocompromised and have been exposed to rabies. No published study testing this empirical recommendation had been published. Thisyakorn U et al evaluated the safety and immunogenicity of pre-exposure human diploid-cell rabies vaccine (HDCV) in HIV-infected children and found that GMTs of rabies antibody in HIV-infected children were significantly lower than those in the control healthy group. GMTs in HIV-infected children with CD4+ T cell count less than 15% was significantly lower than those in HIV-infected children with CD4+ T cell count of 15% or more [77] .
The vaccines were well tolerated. A transient increase of viral load was found in a few patients [78] . Pancharoen C et al [60] reported a 6-year-old HIV-infected girl with severe immunologic suppression (CD4+ T cell count = 4%) who failed to respond to intramuscular preexposure rabies vaccination on days 0,7,28; and intradermal postexposure rabies vaccination at 4 sites on days 0,3,7 and at 2 sites on days 30,90 (double the usual dose).
If possible, the titers of neutralizing antibodies in all HIV-infected, rabiesexposed patients should be determined on days 14 and 28 after rabies vaccination to ensure adequate response. Use of rabies immunoglobulin may be another solution especially in patients with severe immunologic suppression. Further studies are urgently needed to determine the proper methods of rabies immunization in HIVinfected, rabies-exposed persons.
Typhoid vaccine.
HIV infection is an important risk factor for invasive salmonella infection. A study from Thailand showed that a number of children with nontyphoidal nonparatyphoidal salmonella bacteremia were HIV-infected [57] . However, there is no strong evidence supporting that infection with Salmonella typhi is more frequently observed in HIV-infected persons. Kroon FP et al found that the proportion of the HIV-infected persons vaccinated with typhoid vaccine and had protective antibody against S. typhi was lower than that in healthy controls. The antibody response was correlated with CD4+ T cell count [45] .
EFFECT OF CO-MORBID CONDITIONS ON IMMUNE RESPONSE
Malnutrition and concurrent infections are common co-morbidities in patients with HIV infection. Both have a deleterious effect on the immune system and can affect how patients respond to vaccines. A vicious cycle frequently develops:
cytokine release from infections can increase catabolism and decrease intake leading to wasting while malnutrition-related immune dysfunction can lead to more infections [28, 50, 71] . In certain infection such as Mycobacterium avium complex or tuberculosis, weight loss is almost universally seen.
Malnutrition mainly affects T-cell function; therefore, immune response to Tdependent antigenic vaccines can be diminished [21] while antibody response to polysaccharide vaccines are usually preserved [53] .
Opportunistic infections promote the release of inflammatory cytokines, which can increase HIV viral load production and render cells inappropriately activated.
Cell-associated organisms such as Mycobacterium tuberculosis and cytomegalovirus can reduce mature HLA complexes displayed on cell membrane and interfere with natural killer cell, complement and neutralizing antibody function [26, 31] . These can cause an adverse effect on the immune response.
RECOMMENDATIONS
Recommendations for immunization in HIV-infected persons may differ from country to country. Considerations depend on the cost benefit of each vaccine i.e. the availability and affordability of the vaccine and the prevalence and mortality of each vaccine-preventable disease. Recommendations used for developed countries may need to be somewhat different from those recommended for developing countries (see table) . A frequently encountered problem in HIV-infected children is incomplete immunization due to frequent illnesses or lack of a committed caregiver. It is very important to provide "Catch Up" immunization to these children as soon as possible.
Another common occurrence is the inability to locate immunization records especially in orphans. In such circumstances, one should consider these children un-immunized and provide immunization appropriate for age. Alternatively, antibody levels could be measured to determine protection to different infections. Household contacts of HIV-infected persons should also be immunized against common preventable infections.
Summary of important issues include:
1. BCG vaccine can be used for all infants born to HIV-positive mothers in countries where tuberculosis is prevalent. The vaccine should not be administered in symptomatic HIV-infected children and in all HIV-infected adults.
2. DTP vaccine can be used safely in HIV-infected children. DTPa is preferred in developed countries whereas DTPw is commonly used in developing countries. dT or dTpa may be used as a booster vaccine for HIV-infected adults. 
